Avstera Therapeutics Corp.

4:30 PM - 4:45 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
At Avstera, our primary focus is to address the significant unmet need of cancer patients failing to respond, or later developing resistance to existing cutting-edge immunotherapies. With our proprietary pipeline of oncology programs, including an ultra-specific, AMES negative HDAC6i initially targeting Melanoma (AVS100), autologous HDAC6i activated macrophage-based cell therapy (AVS200), and novel mRNA-based cancer vaccine using TEM1 protein (AVS300), we will offer revolutionary therapies targeting solid tumors and addressing a significant unmet need across all tumor types.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
AVS100 - Highly Specific HDAC6i
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CEO & Co-Founder
Avstera Therapeutics Corp.